At Last!This announcement is tremendously encouraging.
As has been noted, this is equivelent to a big pharma partnering for the trial, but far more influential and important, since the invitation comes form this non-profit network, under this radically new approach to running PDAC trials. The FDA panels that ultimately recommend approvals will be paying close attention.
This trial will gain us a great deal of attention and credibility. All we need is more results like we showed last October. And if we can provide more durable and lasting treatment response and extend OS in this trial, ONCY's future is assured, in gold letters.
Note also that the corporate presentation has been greatly expanded to show much more detail about the mBC and PDAC results and it continues to be excellent in my view. If you want some indication they have better talent in the company and are spending ONCY capital wisely, look at the presentaiton.
Remember that we should be expecting some kind of mBC ph 3 trial announcement within the next quarter.
Finally, remember that we should have CRC interim results and some updates on CAR-T findings from Vile and crew at the Mayo clinic.
In my opinion, this kind of announcement is the very thing required to move our share price up to the level where we could be seen as a "mid-size" tuck in acquisition by a big pharma company. If we allow the news to play out over the next three-five months, we are going to have a solid share price. Two ph 3 trials should be worth 1-1.5 bil in market cap, ignoring CRC, and anal indications and ignoring CAR-T.
We the market cap gets to that level, we can be within sight of a substantial buyout.
Good luck to the longs, and in the interest of those coping with cancer diagnosese, may be god speed our progress (and I am not religious).